1. Home
  2. HNNA vs GANX Comparison

HNNA vs GANX Comparison

Compare HNNA & GANX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Hennessy Advisors Inc.

HNNA

Hennessy Advisors Inc.

N/A

Current Price

$10.00

Market Cap

79.2M

Sector

Finance

ML Signal

N/A

Logo Gain Therapeutics Inc.

GANX

Gain Therapeutics Inc.

HOLD

Current Price

$1.85

Market Cap

88.6M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
HNNA
GANX
Founded
1989
2017
Country
United States
United States
Employees
N/A
N/A
Industry
Investment Managers
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
79.2M
88.6M
IPO Year
2005
2021

Fundamental Metrics

Financial Performance
Metric
HNNA
GANX
Price
$10.00
$1.85
Analyst Decision
Strong Buy
Analyst Count
0
4
Target Price
N/A
$7.50
AVG Volume (30 Days)
5.4K
491.3K
Earning Date
05-11-2026
05-13-2026
Dividend Yield
5.57%
N/A
EPS Growth
38.04
31.46
EPS
0.73
N/A
Revenue
$54,590,000.00
$55,180.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
$13.74
N/A
Revenue Growth
3.09
N/A
52 Week Low
$8.90
$1.53
52 Week High
$13.00
$4.34

Technical Indicators

Market Signals
Indicator
HNNA
GANX
Relative Strength Index (RSI) 53.11 47.09
Support Level $9.67 $1.64
Resistance Level $10.29 $2.22
Average True Range (ATR) 0.12 0.13
MACD 0.01 -0.02
Stochastic Oscillator 52.46 16.56

Price Performance

Historical Comparison
HNNA
GANX

About HNNA Hennessy Advisors Inc.

Hennessy Advisors Inc is an investment management company that manages and markets open-end mutual funds branded as the Hennessy Funds. It offers domestic equity, multi-asset sectors, specialty products, and fixed income products. The company earns revenues mainly from investment advisory services and secondarily from shareholder services. Advisory services include managing each fund's portfolio in line with its investment objectives, monitoring compliance and performance, overseeing sub-advisors and other service providers, and handling marketing, distribution, and regulatory reporting. Shareholder services cover investor support and coordination with the fund service provider, with all related fees based on the funds' average daily net asset values.

About GANX Gain Therapeutics Inc.

Gain Therapeutics Inc is a clinical-stage biotechnology company developing novel small-molecule therapeutics to treat diseases across several therapeutic areas, including central nervous system (CNS) disorders, lysosomal storage disorders (LSDs), metabolic disorders, and other diseases that can be targeted through protein degradation, such as oncology. The Company's clinical stage product candidate, GT-02287, is being developed for the treatment of Parkinson's disease with and without GBA1 mutations. The Company generated an extensive preclinical data package providing evidence of the mechanism of action.

Share on Social Networks: